Christian Henry

Chief Executive Officer at PacBio

📍 San Diego, California, United States🔄 Updated September 2026💼 2 investments📅 10 years investing🗓 Last invested Nov 2016𝕏 @upgrade_to_unlock
Angel investor🌍 United States
2
Total investments
0
Early stage
0
Mid stage
1
Late stage
10y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Nov 2016
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. We offer autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgos in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services.
Board Member
Nov 2016
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM™, our proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.
Experience · 2 entries
All (2)
Investments (2)
Board (2)
2016
Board Member
Nov 2016
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. We offer autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgos in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services.
Board Member
Nov 2016
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM™, our proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.